<p>A US district court in Connecticut granted Applied Biosystems's summary judgment motion, dismissing all remaining patent infringement claims filed by Enzo.<br /><br />The company had been seeking royalties
Cervical intraepithelial neoplasia (CIN) is the abnormal growth of precancerous cells in the cervix, usually caused by infection with human papillomavirus (HPV). In addition to the key objective
In the study, the drug showed a clinically and statistically significant reduction in the number of hereditary angioedema (HAE) attacks. Based on the positive results of this study,
The companies mutually agreed to end their collaborative development and marketing agreement on bremelanotide, with King exercising its right to terminate. Under the termination, Palatin has all rights
Bioniche said that the agreement had been reached under the FDA's special protocol assessment (SPA) procedure. The company plans to evaluate its proprietary mycobacterial cell wall-DNA complex (MCC),
The US district court in New Jersey denied the motion for a preliminary injunction by drugmakers Wyeth and Altana who were aiming to stop Israel-based Teva from launching
The tablet combines proton pump inhibitor esomeprazole magnesium with non-steroidal anti-inflammatory drug naproxen, in a single tablet. An new drug application is targeted for the first half of
The candidate, R7128, is a prodrug of PSI-6130, an oral cytidine nucleoside analog polymerase inhibitor of HCV that is being developed through Pharmasset's collaboration with Roche. The Phase
Alvespimycin is a second-generation Hsp90 inhibitor that has demonstrated the potential to disrupt the activity of multiple oncogenes and cell signaling pathways implicated in tumor growth, including HER2,
Bristol, Tennessee-based King Pharmaceuticals said that it “intends to vigorously enforce the patent.” The patent extends through November 25, 2017. Under the federal Hatch-Waxman Act of 1984, any
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.